Current studies Contact Details Country overview Filter Options Quick Search Filter Options Conditions Activated PI3K delta Syndrome (APDS)Active Ankylosing SpondylitisActive Psoriatic ArthritisAdvanced solid tumorsAlzheimer’s DiseaseAnkylosing SpondylitisAnterior Uveitis (AU)Atopic dermatitisAxial SpondyloarthrithisAxial SpondyloarthritisAxial Spondyloarthritis (axSpA)CDKL5 Deficiency DisorderChildhood absence epilepsyChronic Allograft InjuryChronic inflammatory demyelinating polyradiculoneuropathy (CIDP)Chronic Plaque PsoriasisCrohn's DiseaseDravet SyndromeDrug-resistant EpilepsyEarly-stage parkinson's diseaseElectroencephalographic neonatal seizuresEnthesitis-related arthritisEpilepsyEpilepsy with partial onset seizures or generalized tonic-clonic seizuresEpilepsy with partial-onset seizuresFibromyalgiaFocal-Onset SeizuresGeneralized Myasthenia GravisGeneralized Myasthenia Gravis TESTGeneralized pustular psoriasis and erythrodermic psoriasisHealthy ParticipantsHealthy Study ParticipantsHealthy VolunteersHidradenitis SuppurativaHighly drug-resistant focal epilepsyImmune Mediated Necrotizing MyopathyJuvenile absence epilepsyLennox Gastaut SyndromeLeucine-Rich Glioma Inactivated 1 Autoimmune EncephalitisMixed guttate/plaque psoriasisModerate and severe active Rheumatoid ArthritisModerate chronic plaque psoriasisModerate to Severe Chronic Plaque PsoriasisModerate to Severe Plaque PsoriasisModerate to severe PsoriasisModerately to severely active Crohn's DiseaseMyasthenia GravisMyasthenia Gravis, GeneralizedMyelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)Nonradiographic Axial Spondyloarthritisnr-axSpAOcular Myasthenia GravisOsteoporosisPalmoplantar PustulosisParkinson DiseaseParkinson's DiseaseParkinson’s diseaseParoxysmal Nocturnal Hemoglobinuria (PNH)Partial SeizuresPartial seizures with or without secondary generalizationPartial-onset SeizuresPlaque PsoriasisPolyarticular-course Juvenile Idiopathic Arthritis (JIA)Primary Immune ThrombocytopeniaProgressive Supranuclear PalsyPsoriasisPsoriatic Arthritisr-axSpaRestless Legs SyndromeRett SyndromeRheumatoid ArthritisSevere Active Ulcerative ColitisSevere chronic plaque psoriasisSLC6A1 neurodevelopmental disorder (NDD)Stereotypical prolonged seizuresSystemic lupus erythematosusSystemic Lupus Erythematosus (SLE)ThrombocytopeniaThymidine Kinase 2 (TK2) DeficiencyThymidine Kinase 2 Deficiency Studies That Include Woman Man All Studies Incorporating These Age Groups 0-17 18-65 66+ All ages Product Name Bepranemab Bimekizumab Bimzelx® Brivaracetam Briviact® Certolizumab pegol Cimzia® Dapirolizumab pegol Doxecitine and Doxribtimine EVENITY Fintepla Ginisortamab Glovadalen Keppra® Kygevvi Lacosamide Levetiracetam Neupro® RA101495 Romosozumab Rotigotine Rozanolixizumab RYSTIGGO Staccato Alprazolam UCB0022 UCB0107 UCB0599 UCB1381 UCB6114 UCB7665 UCB7853 UCB7858 UCB9741 Vimpat® Zampilimab ZILBRYSQ® Zilucoplan Status Recruiting Not yet recruiting Enrolling by invitation Active, not recruiting Study Title Minimum Age Maximum age Studies That Include Status An Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy 40 Years - All Active, not recruiting An Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy Progressive Supranuclear Palsy Learn More Multicenter, Open Label or Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis 6 Years 17 Years All Active, not recruiting Multicenter, Open Label or Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis Moderate chronic plaque psoriasis Learn More A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis 18 Years - All Active, not recruiting A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis Generalized Myasthenia Gravis Learn More An open-label, single-arm study evaluating the activity, safety, and pharmacokinetics of rozanolixizumab in pediatric study participants with moderate to severe generalized myasthenia gravis 2 Years 17 Years All Active, not recruiting An open-label, single-arm study evaluating the activity, safety, and pharmacokinetics of rozanolixizumab in pediatric study participants with moderate to severe generalized myasthenia gravis Generalized Myasthenia Gravis Learn More A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD) 18 Years 89 Years All Active, not recruiting A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD) Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) Learn More A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa 18 Years - All Active, not recruiting A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Hidradenitis Suppurativa Learn More A Multicenter, Noninterventional, Prospective Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Moderate to Severe Plaque Psoriasis in Daily Practice 18 Years - All Active, not recruiting A Multicenter, Noninterventional, Prospective Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Moderate to Severe Plaque Psoriasis in Daily Practice Plaque Psoriasis Learn More A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis 18 Years - All Active, not recruiting A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis Psoriatic Arthritis Learn More A Phase 3b Exploratory Multicenter Open-Label Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis 18 Years - All Active, not recruiting A Phase 3b Exploratory Multicenter Open-Label Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis Moderate to Severe Plaque Psoriasis Learn More A Phase 2 Open-Label Study of Continuation Treatment with Combination Pyrimidine Nucleosides in Patients with Thymidine Kinase 2 Deficiency (TK2) - - All Active, not recruiting A Phase 2 Open-Label Study of Continuation Treatment with Combination Pyrimidine Nucleosides in Patients with Thymidine Kinase 2 Deficiency (TK2) Thymidine Kinase 2 Deficiency Learn More Open-Label, Single-Arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome 1 Years 23 Months All Active, not recruiting Open-Label, Single-Arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome Dravet Syndrome Learn More
